Estimated effects of ARV-PMTCT, FP, and unwanted fertility on pediatric HIV, 2008–2012.

<p>Note: PY: person-years. CTX: cotrimoxazole.</p

Fertility projections used in analysis.

<p>This figure depicts the three different fertility scenarios used in analysis, from 2007 onwards. TFRc-: Total fertility rate in the absence of contraceptive use; TFR (baseline): Current and projected TFR; wTFR: TFR if only wanted births are considered.</p

Estimated effects of a 80% ARV-PMTCT uptake or 50% FP use among HIV-infected women, by 2012.

<p>Note: All values shown apply to the year 2012 only.</p

Estimated effects of a 80% ARV-PMTCT uptake or 50% FP use among HIV-infected women, 2008–2012.

<p>Note: *The column “Total” estimates the number of events or person years as given by the baseline projection, in the presence of the actual estimated uptake of ARV-PMTCT and FP.</p>**<p>The columns “ARV-PMTCT” and “FP use” indicate the number of events (person characteristic) that would occur in addition in their respective absence. Negative values denote increases.</p><p>Percent estimates: the denominator is give by the number in the absence of the intervention; the numerator indicates the number of events averted. CTX: cotrimoxazole. PY: person-years. FP: Family planning. 80% ARV-PMTCT uptake and 50% FP use (among HIV+ women) are scaled up beginning 2009 and reach their goals by 2012.</p

Numbers of genito-urinal syndromes presenting for case management at STI clinics, by diagnostic and treatment status, 117 low- and middle-income countries, 117 low- and middle-income countries.

<p>Estimated based on the WHO’s 2012 STI burden estimates for 2015, with extrapolation to 2021 reflecting the global STI strategy’s burden reduction and diagnostic and treatment coverage targets, as described in Methods and in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0170773#pone.0170773.t001" target="_blank">Table 1</a>. The estimated annual GUD cases total 16.2 million in both 2015 and 2021; the y-axis was capped at a lower maximum for readability of the shown sub-sets of cases.</p

Unit costs of STI-related service deliveries, with unit cost varying by income tier.

<p>Unit costs of STI-related service deliveries, with unit cost varying by income tier.</p

Service needs and costs for implementation of the global STI control strategy 2016–2021 across low and middle-income countries.

<p>Service needs and costs for implementation of the global STI control strategy 2016–2021 across low and middle-income countries.</p

Unit costs of diagnostic and treatment commodities (unit cost assumed equal across all countries).

<p>Unit costs of diagnostic and treatment commodities (unit cost assumed equal across all countries).</p

HIV prevalence among women attending antenatal clinics, 1991–2007.

<p>Data from urban clinics (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003729#pone-0003729-g001" target="_blank">Figure 1a</a>) and rural clinics (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003729#pone-0003729-g001" target="_blank">Figure 1b</a>) are shown in the gray lines. The smooth curve produced by EPP is shown in the dark dashed line for each region.</p

Annual number of new child infections (Figure 2a) and adult deaths (Figure 2b), 1980–2007.

<p>Annual number of new child infections (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003729#pone-0003729-g002" target="_blank">Figure 2a</a>) and adult deaths (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0003729#pone-0003729-g002" target="_blank">Figure 2b</a>), 1980–2007.</p